Adult obesity and overweight
Chinese mainland
Phase III; 30-week follow-up for the primary efficacy endpoint completed in July 2026.
FOUNDED IN 2014
Medicines for metabolic disease.
Innogen is a science-driven biopharmaceutical company developing innovative, high-quality medicines for diabetes, obesity and other metabolic diseases. We are committed to making these medicines accessible and affordable.
About Innogen
Our first medicine is approved for adult type 2 diabetes in mainland China and Macao, and has been on mainland China’s national reimbursement list since 1 January 2026.
We are also studying this medicine for obesity in Australia and pursuing registration for adult type 2 diabetes in Brazil.
Explore development programsEfsubaglutide alfa
Approved use and ongoing development
Full development pipeline
Diabegone
Efsubaglutide alfa
Innogen’s internally developed, humanized, long-acting GLP-1 receptor agonist
Approved for adult type 2 diabetes in mainland China and Macao. Further indications and dosing regimens remain under investigation.
Medicine resourcesEfsubaglutide alfa combines human GLP-1 with the Fc fragment of human IgG2. Innogen is studying its potential in other conditions and patient populations, as well as new dosing regimens.
Investigational uses and regimens · not approved
Adult type 2 diabetes: dosing every two weeks
Chinese mainland
A supplemental application for dosing once every two weeks was accepted in July 2026.
Our development platform
From discovery to manufacturing
Innogen’s proprietary recombinant-protein platform connects molecular design and candidate screening with clinical development and manufacturing processes. Explore this work and the evidence behind efsubaglutide alfa, from cell studies to clinical trials.
Explore the scienceThe company
From discovery to a marketed medicine.
Founded in 2014 by Qinghua Wang, the inventor of efsubaglutide alfa, Innogen builds on its own drug discovery and development platform. Its ambition is to develop first-in-class and best-in-class medicines for people with metabolic disease in China and worldwide.
Our company and leadership
The path to today
Explore Innogen’s history2014—2015
Innogen was founded and established an R&D center in Shanghai’s Zhangjiang Medical Valley.
2018—2023
Efsubaglutide alfa progressed from Phase I research to completion of two Phase IIb/III studies in type 2 diabetes in China.
2025
Efsubaglutide alfa received approvals for adult type 2 diabetes in mainland China and Macao; Innogen listed on the HKEX Main Board.
1,900+
medical institutions in mainland China
As reported in the 25 August 2026 interim results, efsubaglutide alfa had reached more than 1,900 medical institutions in mainland China. Its inclusion in the National Reimbursement Drug List took effect on 1 January 2026.
Read the interim results ↗From Innogen
Research and company news
All newsTwo contract manufacturing sites receive ANVISA GMP certification
Two contract sites manufacturing efsubaglutide alfa in China received GMP certificates from Brazil’s ANVISA. Both sites are owned and operated by an independent third party. Certification concerns manufacturing and quality systems; authorization to market the medicine in Brazil is a separate process.
